

# Recombinant Human Endothelial-Monocyte Activating Polypeptide II (rHuEMAP-II)

## PrimeGene Technical Data Sheet

<b>Catalog Number:</b>	103-11
<b>Source:</b>	<i>Escherichia coli</i> .
<b>Molecular Weight:</b>	Approximately 18.2 kDa, a single non-glycosylated polypeptide chain containing 166 amino acids.
<b>Quantity:</b>	5µg/20µg/1000µg
<b>AA Sequence:</b>	SKPIDVSRLD LRIGCIITAR KHPDADSLYV EEVDVGEIAP RTVVSGLVNH VPLEQMQRNM VILLCNLKPA KMRGVLSQAM VMCASSPEKI EILAPPNGSV PGDRITFDAF PGEPDKELNP KKKIWEQIQP DLHTNDECVA TYKGVPEVK GKGVCRAQTM SNSGIK
<b>Purity:</b>	> 98 % by SDS-PAGE and HPLC analyses.
<b>Biological Activity:</b>	Fully biologically active when compared to standard. The ED <sub>50</sub> as determined by the apoptotic effect using serum free human MCF-7 cells is less than 40 ng/ml, corresponding to a specific activity of > 2.5 × 10 <sup>4</sup> IU/mg.
<b>Physical Appearance:</b>	Sterile Filtered White lyophilized (freeze-dried) powder.
<b>Formulation:</b>	Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.
<b>Endotoxin:</b>	Less than 1 EU/µg of rHuEMAP-II as determined by LAL method.
<b>Reconstitution:</b>	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
<b>Shipping:</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage:</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"><li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li><li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li><li>● 3 months, -20 to -70 °C under sterile conditions after reconstitution.</li></ul>
<b>Usage:</b>	This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. <b>NOT FOR HUMAN USE.</b>

### ***Human Endothelial-Monocyte Activating Polypeptide II***

Endothelial-Monocyte Activating Polypeptide II (EMAP-II) is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues.